MEDICATION TREATMENT OF SEVERE DEPRESSION

严重抑郁症的药物治疗

• 批准号: 7604176
• 负责人: BARNETT MEYERS
• 金额: $ 0.66万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604176
• 关键词: Acute; Age; Computer Retrieval of Information on Scientific Projects Database; Condition; Disease remission; Dose; Double-Blind Method; Funding; Glucose; Grant; Institution; Lipids; Mental Depression; Metabolic; Outcome; Outpatients; Partial Remission; Pharmaceutical Preparations; Pharmacotherapy; Phase; Placebo Control; Placebos; Rate; Research; Research Personnel; Resources; Selective Serotonin Reuptake Inhibitor; Sertraline; Source; United States National Institutes of Health; Week; atypical antipsychotic; base; day; olanzapine; older patient; psychotic depression; treatment trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a double-blind placebo controlled 12-week study of the acute treatment of psychotic depression. Subjects who acheive partial remission enter a stabilization phase augmentation treatment trial on an outpatient basis. The primary objectives of this study are: -To compare the efficacy of two pharmacotherapies for psychotic depression: high dose SSRI (sertraline 150-200mg/day) combined with an atypical antipsychotic (olanzapine 10-20 mg/day) versus the atypical anthipychotic plus placebo. (olanzapine 10-20mg/day). -To determine whether older patients have lower remission rates and poorer tolerability to the pharmacotherapy conditions. In addition, changes in glucose and lipid levels will be used to determine whether old age influences the metabolic effects of olanzapine. Setraline and Olansapine levels will be obtained to assess their contribution to outcomes.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项双盲安慰剂控制的12周研究，对精神病性抑郁症的急性治疗。获得部分缓解的受试者以门诊的身份进入稳定阶段增强治疗试验。 这项研究的主要目标是： - 比较两种药物治疗的精神抑郁症的功效：高剂量SSRI（舍曲林150-200mg/day）与非典型的抗精神病药（Olanzapine 10-20 mg/day）相比，与非典型的artthipychotic arthipychotic plus plus安慰剂相比。 （奥氮平10-20mg/天）。 - 确定老年患者的缓解率是否较低，对药物治疗状况的耐受性较差。 此外，葡萄糖和脂质水平的变化将用于确定老年是否影响奥氮平的代谢作用。将获得Setraline和Olansapine水平，以评估其对结果的贡献。